"Tamoxifen" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
One of the SELECTIVE ESTROGEN RECEPTOR MODULATORS with tissue-specific activities. Tamoxifen acts as an anti-estrogen (inhibiting agent) in the mammary tissue, but as an estrogen (stimulating agent) in cholesterol metabolism, bone density, and cell proliferation in the ENDOMETRIUM.
| Descriptor ID |
D013629
|
| MeSH Number(s) |
D02.455.426.559.389.150.700.900
|
| Concept/Terms |
ICI-46474- ICI-46474
- ICI 46474
- ICI46474
- ICI-46,474
- ICI 46,474
- ICI46,474
|
Below are MeSH descriptors whose meaning is more general than "Tamoxifen".
Below are MeSH descriptors whose meaning is more specific than "Tamoxifen".
This graph shows the total number of publications written about "Tamoxifen" by people in this website by year, and whether "Tamoxifen" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 3 | 1 | 4 |
| 1996 | 2 | 3 | 5 |
| 1997 | 5 | 4 | 9 |
| 1998 | 4 | 2 | 6 |
| 1999 | 2 | 4 | 6 |
| 2000 | 4 | 2 | 6 |
| 2001 | 1 | 1 | 2 |
| 2002 | 0 | 1 | 1 |
| 2003 | 5 | 3 | 8 |
| 2004 | 8 | 2 | 10 |
| 2005 | 8 | 8 | 16 |
| 2006 | 4 | 3 | 7 |
| 2007 | 0 | 2 | 2 |
| 2008 | 2 | 1 | 3 |
| 2009 | 5 | 3 | 8 |
| 2010 | 3 | 5 | 8 |
| 2011 | 5 | 6 | 11 |
| 2012 | 4 | 6 | 10 |
| 2013 | 1 | 5 | 6 |
| 2014 | 3 | 9 | 12 |
| 2015 | 2 | 2 | 4 |
| 2016 | 3 | 4 | 7 |
| 2017 | 1 | 7 | 8 |
| 2018 | 1 | 5 | 6 |
| 2019 | 1 | 3 | 4 |
| 2020 | 1 | 5 | 6 |
| 2021 | 1 | 4 | 5 |
| 2022 | 0 | 5 | 5 |
| 2023 | 0 | 4 | 4 |
| 2024 | 1 | 0 | 1 |
| 2025 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Tamoxifen" by people in Profiles.
-
A mouse model engineered to spatiotemporally control Cre expression in progesterone receptor positive cells?. Biol Reprod. 2025 Jul 13; 113(1):83-96.
-
Breast Cancer Index in Premenopausal Women With Early-Stage Hormone Receptor-Positive Breast Cancer. JAMA Oncol. 2024 Oct 01; 10(10):1379-1389.
-
The Population-level Effect of Adjuvant Therapies on Breast Cancer Recurrence: Application of the Trend-in-Trend Design. Epidemiology. 2024 09 01; 35(5):660-666.
-
Breast Articles From 2023: Informing Practice Across the Continuum of Care. Ann Surg Oncol. 2024 Jul; 31(7):4470-4476.
-
Racial and Ethnic Disparities in Outcomes After Breast-Conserving Therapy and Endocrine Therapy for DCIS: A Post-Hoc Analysis of the NSABP B-35 Randomized Clinical Trial. Ann Surg Oncol. 2023 Dec; 30(13):8404-8411.
-
MicroRNA regulation of the serine synthesis pathway in endocrine-resistant breast cancer cells. Endocr Relat Cancer. 2023 11 01; 30(11).
-
Radiotherapy versus low-dose tamoxifen following breast-conserving surgery for low-risk and estrogen receptor-positive breast ductal carcinoma in situ: an international open-label randomized non-inferiority trial (TBCC-ARO DCIS Trial). BMC Cancer. 2023 Sep 14; 23(1):865.
-
Steroid receptor coactivator 3 is a key modulator of regulatory T cell-mediated tumor evasion. Proc Natl Acad Sci U S A. 2023 06 06; 120(23):e2221707120.
-
Effects of Genetic Polymorphisms of Drug Metabolizing Enzymes and co-Medications on Tamoxifen Metabolism in Black South African Women with Breast Cancer. Clin Pharmacol Ther. 2023 07; 114(1):127-136.
-
Evaluation of the Sensitivity to Endocrine Therapy Index and 21-Gene Breast Recurrence Score in the SWOG S8814 Trial. J Clin Oncol. 2023 04 01; 41(10):1841-1848.